AMGN241101C322500
- 6.06
- +0.26+4.48%
Amgen Newsroom
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Apple, Microsoft, Exxon, and More Stocks to Watch
Amgen Keeps Quarterly Dividend at $2.25 a Share, Payable Dec. 9 to Shareholders of Record Nov. 18
Express News | Amgen Announces 2024 Fourth Quarter Dividend
Amgen Likely to See Q3 Miss, Long-Term Positive Revenue Growth, Oppenheimer Says
Amgen Inc. (NASDAQ:AMGN) Shares Could Be 39% Below Their Intrinsic Value Estimate
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Earnings Preview: Amgen to Report Financial Results Post-market on October 30
$Amgen(AMGN.US)$ is scheduled to release its financial results post-market on October 30 ET. Earnings PreviewAnalysts estimate $Amgen(AMGN.US)$ to post revenue of USD8.50B for 2024Q3, up 23.17% YOY;
AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS
A Closer Look at Amgen's Options Market Dynamics
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
Dow's Nearly 300-Point Drop Led By Losses For Shares Of McDonald'S, Boeing
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Amgen (AMGN) Receives a Buy From Piper Sandler
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $335
Bernstein Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Market Chatter: Amgen to Launch Biosimilar of Eylea After Court Denies Regeneron's Stay Request
Navigating 14 Analyst Ratings For Amgen
Express News | Amgen Says It Is Launching Biosimilar of Eye Drug Eylea After U.S. Appeals Court Ruling in Regeneron Patent Case
Cantor Fitzgerald Reiterates Overweight on Amgen, Maintains $405 Price Target